1. Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13). Issue 1 (22nd February 2023) Authors: Carbery, Isabel; Burdge, Gemma; Clark, Tanya; Broglio, Giacomo; Greer, Dan; Alakkari, Alaa; Selinger, Christian Philipp Journal: BMJ open gastroenterology Issue: Volume 10:Issue 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P200 Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations. (19th June 2022) Authors: Burdge, Gemma; Hardman, Alice; Selinger, Christian Journal: Gut Issue: Volume 71(2022)Supplement 1 Page Start: A138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗